BridgeMD
New treatment option for Contrast-Induced Acute Kidney Injury
Official title ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions
ClinicalTrials.gov ID: NCT04936607
What this study is testing
- What it's testing
- The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and/or percutaneous coronary intervention (PCI).
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years;
- Planned coronary angiogram and/or PCI;
- Willingness to participate and to attend study visits;
- Expected life expectancy ≥6 months.
You likely can't join if
- Cardiogenic or non-cardiogenic shock at the time of the procedure;
- Emergent procedures (e.g. STEMI);
- Iodine-based contrast media received within 2 days;
- Presence of Intra-Aortic Balloon Pump (IABP);
- Cardiac arrest within 24 hours;
- Pre-procedural AKI defined using the modified KDIGO criteria within 7 days;
See the full eligibility criteria
- Age ≥18 years;
- Planned coronary angiogram and/or PCI;
- Willingness to participate and to attend study visits;
- Expected life expectancy ≥6 months.
- Cardiogenic or non-cardiogenic shock at the time of the procedure;
- Emergent procedures (e.g. STEMI);
- Iodine-based contrast media received within 2 days;
- Presence of Intra-Aortic Balloon Pump (IABP);
- Cardiac arrest within 24 hours;
- Pre-procedural AKI defined using the modified KDIGO criteria within 7 days;
- Renal replacement therapy;
- Severe aortic or mitral disease;
- LVEF \<30%.
The study team makes the final eligibility decision.
Where it's taking place
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montreal, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.